GTHP (Guided Therapeutics) Cyclically Adjusted Revenue per Share: $0.00 (As of Mar. 2026)


GTHP Guided Therapeutics Inc GTHP
18 GF Score
Price $0.28
! 4 Warning Signs
View Full Analysis

What is Guided Therapeutics Cyclically Adjusted Revenue per Share?

Guided Therapeutics GTHP +14.29% 18 Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus rates GTHP with a GF Score™ of 18/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Guided Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Guided Therapeutics was -3.40% per year. The lowest was -46.50% per year. And the median was -19.30% per year.

As of today (2026-07-08), Guided Therapeutics's current stock price is $0.28. Guided Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.00. Guided Therapeutics's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guided Therapeutics was 2.37. The lowest was 0.01. And the median was 0.02.


Guided Therapeutics  (OTCPK:GTHP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Guided Therapeutics was 2.37. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Guided Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Guided Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Guided Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guided Therapeutics Cyclically Adjusted Revenue per Share Chart

Guided Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 57.89 0.00 56.20 0.00 50.47

Guided Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 55.81 53.24 50.47 0.00

GTHP vs CTSO, IRIX, ICCM: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Guided Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guided Therapeutics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Guided Therapeutics's Cyclically Adjusted PS Ratio falls into.


GTHP
18GF Score
Guided Therapeutics Inc GTHP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guided Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Guided Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/330.2130*330.2130
=0.000

Current CPI (Mar. 2026) = 330.2130.

Guided Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 119.000 241.432 162.759
201703 21.000 243.801 28.443
201706 43.500 244.955 58.640
201709 3.667 246.819 4.906
201712 1.726 246.524 2.312
201803 0.002 249.554 0.003
201806 0.003 251.989 0.004
201809 0.005 252.439 0.007
201812 0.016 251.233 0.021
201903 0.006 254.202 0.008
201906 0.000 256.143 0.000
201909 0.000 256.759 0.000
201912 0.005 256.974 0.006
202003 0.000 258.115 0.000
202006 0.000 257.797 0.000
202009 0.001 260.280 0.001
202012 0.002 260.474 0.003
202103 0.000 264.877 0.000
202106 0.000 271.696 0.000
202109 0.001 274.310 0.001
202112 0.004 278.802 0.005
202203 0.000 287.504 0.000
202206 0.000 296.311 0.000
202209 0.000 296.808 0.000
202212 0.000 296.797 0.000
202303 0.000 301.836 0.000
202306 0.001 305.109 0.001
202309 0.000 307.789 0.000
202312 0.001 306.746 0.001
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000
202412 0.000 315.605 0.000
202503 0.000 319.799 0.000
202506 0.001 322.561 0.001
202509 0.001 324.800 0.001
202512 0.007 324.054 0.007
202603 0.000 330.213 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Guided Therapeutics (GTHP) has a Cyclically Adjusted Revenue per Share of $0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guided Therapeutics and its competitors.
Is Guided Therapeutics' Cyclically Adjusted Revenue per Share too high?
Guided Therapeutics' current Cyclically Adjusted Revenue per Share is $0.00. Overall, Guided Therapeutics has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Guided Therapeutics' Cyclically Adjusted Revenue per Share compare to CTSO and IRIX?
Guided Therapeutics' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Guided Therapeutics and its competitors. Guided Therapeutics's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guided Therapeutics stock overvalued right now?
Guided Therapeutics (GTHP) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Guided Therapeutics' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Guided Therapeutics (GTHP), the current Cyclically Adjusted Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guided Therapeutics Business Description

Address 5835 Peachtree Corners East, Suite B, Peachtree Corners, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and the extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
18GF Score

Get the complete analysis for GTHP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price